Literature DB >> 25371154

Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma.

Masaki Kaibori1, Nobuaki Shikata, Tatsuma Sakaguchi, Morihiko Ishizaki, Kosuke Matsui, Hiroya Iida, Yoshito Tanaka, Hirokazu Miki, Richi Nakatake, Tadayoshi Okumura, Katsuji Tokuhara, Kentaro Inoue, Jouji Wada, Michio Oda, Mikio Nishizawa, Masanori Kon.   

Abstract

BACKGROUND: Aberrant signaling mediated by the mammalian target of rapamycin (mTOR) occurs at high frequency in hepatocellular carcinoma (HCC), indicating that mTOR is a candidate for targeted therapy. mTOR forms two complexes called mTORC1 (mTOR complexed with raptor) and mTORC2 (mTOR complexed with rictor). There are minor studies of the expression kinetics of mTORC1 and mTORC2 in HCC.
METHODS: We studied 62 patients with HCC who underwent curative resection. We used univariate and multivariate analyses to identify factors that potentially influence disease and overall survival after hepatectomy. The mRNA and protein levels of mTOR, rictor and raptor in cancer and non-cancer tissues were analyzed using quantitative RT-PCR, immunohistochemistry and Western blotting. RESULTS/
CONCLUSION: High ratio of the levels of rictor and raptor mRNAs in tumors was identified as independent prognostic indicators for disease-free survival. Low and high levels of preoperative serum albumin and mTOR mRNA in the tumor, respectively, were identified as independent indicators of overall survival. HCC is likely to recur early after hepatic resection in patients with high levels of mTOR and rictor mRNAs and high rictor/raptor ratios in cancer tissues. We conclude that analysis of mTOR expression in cancer tissues represents an essential strategy to predict HCC recurrence after curative treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25371154     DOI: 10.1007/s10620-014-3417-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.

Authors:  Yonghao Yu; Sang-Oh Yoon; George Poulogiannis; Qian Yang; Xiaoju Max Ma; Judit Villén; Neil Kubica; Gregory R Hoffman; Lewis C Cantley; Steven P Gygi; John Blenis
Journal:  Science       Date:  2011-06-10       Impact factor: 47.728

4.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

5.  Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.

Authors:  Zhi Hong Lu; Mark B Shvartsman; Andrew Y Lee; Jenny M Shao; Mollianne M Murray; Raleigh D Kladney; Dong Fan; Stan Krajewski; Gary G Chiang; Gordon B Mills; Jeffrey M Arbeit
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 6.  Updates of mTOR inhibitors.

Authors:  Hongyu Zhou; Yan Luo; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2010-09       Impact factor: 2.505

7.  Simple technique for detecting RNA viruses by PCR in single sections of wax embedded tissue.

Authors:  C J Woodall; N J Watt; G B Clements
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

8.  Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.

Authors:  Wolfgang Sieghart; Thorsten Fuereder; Katharina Schmid; Daniel Cejka; Johannes Werzowa; Fritz Wrba; Xiaowei Wang; Diego Gruber; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Volker Wacheck
Journal:  Transplantation       Date:  2007-02-27       Impact factor: 4.939

9.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

10.  Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.

Authors:  Pengda Liu; Wenjian Gan; Hiroyuki Inuzuka; Adam S Lazorchak; Daming Gao; Omotooke Arojo; Dou Liu; Lixin Wan; Bo Zhai; Yonghao Yu; Min Yuan; Byeong Mo Kim; Shavali Shaik; Suchithra Menon; Steven P Gygi; Tae Ho Lee; John M Asara; Brendan D Manning; John Blenis; Bing Su; Wenyi Wei
Journal:  Nat Cell Biol       Date:  2013-10-27       Impact factor: 28.824

View more
  12 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

2.  The role of the PTEN/mTOR axis in clinical response of rectal cancer patients.

Authors:  Oya Orun; Sevgi Özden; Olca Kılınç; Pınar Mega Tiber; Pelin Yonar; Zerrin Özgen; Hazan Özyurt
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.742

3.  Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Authors:  Meghan Morrison Joly; Donna J Hicks; Bayley Jones; Violeta Sanchez; Monica Valeria Estrada; Christian Young; Michelle Williams; Brent N Rexer; Dos D Sarbassov; William J Muller; Dana Brantley-Sieders; Rebecca S Cook
Journal:  Cancer Res       Date:  2016-04-25       Impact factor: 12.701

4.  Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.

Authors:  Yu-Hai Bian; Jia Xu; Wen-Yi Zhao; Zi-Zhen Zhang; Lin Tu; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 5.  Genetic alterations in hepatocellular carcinoma: An update.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

6.  Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.

Authors:  Xingmei Liang; Ran Sun; Xiulan Zhao; Yanhui Zhang; Qiang Gu; Xueyi Dong; Danfang Zhang; Junying Sun; Baocun Sun
Journal:  J Cell Mol Med       Date:  2017-07-12       Impact factor: 5.310

7.  Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.

Authors:  Katharina M Schmidt; Claus Hellerbrand; Petra Ruemmele; Christoph W Michalski; Bo Kong; Alexander Kroemer; Christina Hackl; Hans J Schlitt; Edward K Geissler; Sven A Lang
Journal:  Oncotarget       Date:  2017-04-11

8.  Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.

Authors:  Katharina M Schmidt; Peter Dietrich; Christina Hackl; Jessica Guenzle; Peter Bronsert; Christine Wagner; Stefan Fichtner-Feigl; Hans J Schlitt; Edward K Geissler; Claus Hellerbrand; Sven A Lang
Journal:  Neoplasia       Date:  2018-11-04       Impact factor: 5.715

Review 9.  The role of RICTOR downstream of receptor tyrosine kinase in cancers.

Authors:  Ahlem Jebali; Nicolas Dumaz
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  CD24 blunts the sensitivity of retinoblastoma to vincristine by modulating autophagy.

Authors:  Jie Sun; Dongju Feng; Huiyu Xi; Jiajing Luo; Zewei Zhou; Qinghuai Liu; Yun Chen; Qing Shao
Journal:  Mol Oncol       Date:  2020-06-13       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.